Azitra, Inc. (AZTR)
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Azitra, Inc.
NYSE:AZTRHealthcare · Biotechnology
-26.80%$1.12
AH Close$1.12+0.00%vs close
AH$1.12+0.00%vs close
Mkt Cap$6.79M
Float–
O/S6.06M
Inst Own32.0%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$0
Net Income-$10.96M
Total Assets$5.03M
Free Cash Flow-$11.41M
Debt & Equity
Debt 10%
Equity 90%
Total Debt$422K
Total Equity$3.8M
Shares Outstanding
Short Interest
Split History3 splits · 3 reverse
2-year cumulative
1:66.6
Nasdaq bars a compliance period at 1:250
- 1:10Reverse splitOct 26, 202610 shares → 1
- 1:6.7Reverse splitAug 21, 20256.7 shares → 1
- 1:30Reverse splitJul 1, 202430 shares → 1
Balance Sheet Details
Assets$5.03M
Liabilities$1.22M
Accounts Receivable$141K
Accounts Payable$399K
Inventory$0
PP&E (Net)$962K
Goodwill$0
Intangible Assets$317K
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Revenue | $0 | $8K | $686K | $284K | $110K |
| YoY Growth | - | -98.9% | 141.5% | 158.2% | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $8K | $686K | $284K | $110K |
| Gross Margin | - | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and Development | $4.84M | $4.72M | $3.64M | $6.1M | $5.38M |
| Selling, General, and Administrative | $6.13M | $6.27M | $4.49M | $3.64M | $3.95M |
| Other | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $10.97M | $10.99M | $8.14M | $9.74M | $9.33M |
| Operating Income (EBIT) | -$10.97M | -$10.99M | -$7.45M | -$9.45M | -$9.22M |
| Operating Margin | - | -146468.5% | -1086.1% | -3328.7% | -8383.1% |
| Interest Expense | $8K | $12K | $168K | $252K | $67K |
| Interest Income | $70K | $123K | $2K | $5K | $9K |
| Other Income (Expense) | $20K | $2.03M | -$3.82M | -$1.23M | $282K |
| Income Before Tax (EBT) | -$10.95M | -$8.96M | -$11.27M | -$10.68M | -$8.94M |
| Income Tax Expense | $8K | $9K | $17K | $0 | $0 |
| Net Income | -$10.96M | -$8.97M | -$11.28M | -$10.68M | -$8.94M |
| Net Income Margin | - | -119566.6% | -1644.9% | -3760.7% | -8127.0% |
| Supplementary Data | |||||
| EPS | -2.25 | -15.78 | -208.74 | -222.33 | -193.55 |
| Diluted EPS | -2.25 | -15.78 | -208.74 | -222.33 | -193.55 |
| Weighted Average OS | 4.87M | 568,240 | 60,548 | 60,493 | 60,493 |
| EBITDA | -$10.49M | -$8.5M | -$10.67M | -$10.02M | -$8.79M |
| EBITDA Margin | - | -113307.5% | -1555.9% | -3529.0% | -7989.0% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Assets | |||||
| Current Assets | |||||
| Cash and Cash Equivalents | $2.07M | $4.55M | $1.8M | $3.49M | $8.04M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $2.07M | $4.55M | $1.8M | $3.49M | $8.04M |
| Accounts Receivable | $141K | $102K | $223K | $266K | $334K |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $0 | $4K | $68K | $217K | $0 |
| Total Current Assets | $3.02M | $5.23M | $2.54M | $4.14M | $8.49M |
| Long-Term Assets | |||||
| Property, Plant & Equipment Net | $962K | $1.21M | $1.58M | $1.96M | $947K |
| Goodwill | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $317K | $246K | $211K | $220K | $98K |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $727K | $678K | $790K | $848K | $668K |
| Total Long-Term Assets | $2.01M | $2.13M | $2.58M | $3.03M | $1.71M |
| Other Assets | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $5.03M | $7.36M | $5.12M | $7.17M | $10.2M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | $399K | $490K | $897K | $785K | $718K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $6.26M | $12K | $0 | $0 | $1K |
| Current Unearned Revenue | $0 | $0 | $0 | $156K | $15K |
| Other Current Liabilities | $237K | $33K | $145K | $27K | $43K |
| Total Current Liabilities | $1.07M | $1.38M | $1.6M | $2.22M | $1.21M |
| Long-Term Liabilities | |||||
| Long-Term Debt | $0 | $0 | $0 | $6.6M | $992K |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $381 | $35K | $33.76M | $33.77M |
| Total Long-Term Liabilities | $156K | $285K | $599K | $41.21M | $34.76M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.22M | $1.66M | $2.2M | $43.43M | $35.97M |
| Stockholders' Equity | |||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $1K | $763 | $1K | $104 | $104 |
| Retained Earnings | -$68.52M | -$57.57M | -$48.6M | -$37.31M | -$26.63M |
| Comprehensive Income & Other | $0 | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $72.32M | $63.26M | $51.51M | $1.05M | $868K |
| Total Equity | $3.8M | $5.7M | $2.91M | -$36.26M | -$25.77M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $5.03M | $7.36M | $5.12M | $7.17M | $10.2M |
| Supplementary Data | |||||
| Total Debt | $422K | $556K | $886K | $7.73M | $992K |
| Net Debt | -$1.65M | -$4M | -$910K | $4.24M | -$7.05M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Operating Activities | |||||
| Net Income | -$10.96M | -$8.97M | -$11.28M | -$10.68M | -$8.94M |
| Depreciation & Amortization | $453K | $448K | $426K | $406K | $85K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $63K | $245K | $152K | $184K | $306K |
| Changes in Working Capital: | |||||
| Accounts Receivable | -$39K | $133K | $43K | $67K | $194K |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $0 | -$141K | -$69K | $421K | $283K |
| Other Working Capital | -$758K | -$434K | -$727K | -$177K | $169K |
| Total Working Capital Change | -$797K | -$442K | -$753K | $311K | $646K |
| Other Non-Cash Items | $13K | -$1.47M | $4.1M | $1.43M | -$165K |
| Net Cash from Operating | -$11.22M | -$10.18M | -$7.36M | -$8.35M | -$8.07M |
| Investing Activities | |||||
| Capital Expenditures | -$24K | -$9K | -$27K | -$33K | -$446K |
| Acquisitions | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | -$159K | -$371K | -$292K | -$304K | -$206K |
| Net Cash from Investing | -$183K | -$379K | -$318K | -$337K | -$652K |
| Financing Activities | |||||
| Debt Repaid | $16K | $15K | $7K | -$4.35M | -$984K |
| Common Stock Issuance | $9.03M | $13.35M | $5.99M | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$97K | -$18K | $0 | -$215K | $8K |
| Net Cash from Financing | $8.92M | $13.32M | $5.98M | $4.13M | $993K |
| Forex Effect | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$2.49M | $2.76M | -$1.7M | -$4.55M | -$7.73M |
| Supplementary Data | |||||
| Operating Cash Flow | -$11.22M | -$10.18M | -$7.36M | -$8.35M | -$8.07M |
| Capital Expenditure | -$186K | -$379K | -$318K | -$341K | -$652K |
| Free Cash Flow | -$11.41M | -$10.56M | -$7.68M | -$8.69M | -$8.72M |
| Cash at Beginning | $4.55M | $1.8M | $3.49M | $8.04M | $15.77M |
| Cash at End | $2.07M | $4.55M | $1.8M | $3.49M | $8.04M |